VAL-083 updated results, page-7

Hard to say. I briefly looked at that earlier and had a hard time confirming those numbers from the graph they provided (https://d1io3yog0oux5.cloudfront.net/_88a046bc8920bae9b8651b05712f7d5a/kintara/db/203/2265/pdf/SNO+MDACC+2020-Final.pdf). I am also not sure if they use exactly the same criteria for determining PFS as Kazia.

However, Kintara claims a 95% confidence interval of 7.6-10.8 months for median PFS, while Kazia claims a confidence interval of 7.3-10.0 months. In that respect, they are actually pretty similar. I personally do not think patients would prefer IV chemotherapy to a targeted therapeutic pill in terms of convenience and quality of life. I have heard some GBM patients forego any current treatment because of this. While I do think Kintara's drug shows some promise, I find some things suspect about the company who owns the rights. I wonder, though, if one reason James rushed to do the GBM AGILE before completing the phase 2 was to help reach first to market and have a higher chance of becoming the new standard of care.